TY - JOUR
T1 - Impairment in work and activities of daily life in patients with psoriasis
T2 - results of the prospective BioCAPTURE registry
AU - van Hal, Tamara W
AU - van den Reek, Juul M P A
AU - Wenink, Mark H
AU - Otero, Marisol E
AU - Ossenkoppele, Paul M
AU - Njoo, Marcellus D
AU - Oostveen, Annet
AU - Peters, Bas
AU - Tjioe, Milan
AU - Kop, Else N
AU - Körver, John E M
AU - Dodemont, Sharon R P
AU - Kleinpenning, Marloes M
AU - Berends, Maartje A M
AU - Veldkamp, Wendelien R
AU - van Doorn, Martijn B A
AU - Mommers, Johannes M
AU - Lindhout, Robert-Jan
AU - Kuijpers, Astrid L A
AU - van Lümig, Paula P
AU - de Jonge, C Els J
AU - Tupker, Ron A
AU - Hendricksen, Judith
AU - Keijsers, Romy R
AU - van den Hoogen, Frank H J
AU - Vriezekolk, Johanna E
AU - de Jong, Elke M G J
PY - 2024/1/23
Y1 - 2024/1/23
N2 - Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, ?<?0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, ?=?0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12?months, ?=?0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.
AB - Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors. Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations. We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, ?<?0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, ?=?0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12?months, ?=?0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning. Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.
KW - Psoriasis
KW - activities of daily living
KW - work
KW - Humans
KW - Activities of Daily Living
KW - Prospective Studies
KW - Cognition
KW - Registries
U2 - 10.1080/09546634.2024.2304025
DO - 10.1080/09546634.2024.2304025
M3 - Article
SN - 1471-1753
VL - 35
JO - The Journal of dermatological treatment
JF - The Journal of dermatological treatment
IS - 1
M1 - 2304025
ER -